Cover Image
市場調查報告書

Urokinase的中國市場:2010年∼2019年

Investigation Report on China Urokinase Market 2010-2019

出版商 China Research and Intelligence 商品編碼 337515
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Urokinase的中國市場:2010年∼2019年 Investigation Report on China Urokinase Market 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 30 Pages
簡介

在2010年僅1,820萬人民幣的中國的Urokinase銷售額,之後便以12.30%的年複合成長率擴大,到2014年達成2,895萬人民幣的規模,其中48.5%為NDPHARM所佔。

本報告提供中國的Urokinase的專利及核準情況,提供您銷售額·銷售量的變化與預測,價格趨勢,主要的製藥公司及其市場佔有率,競爭環境與其展望,還有主要製造商的簡介等資訊。

第1章 Urokinase的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Urokinase的市場簡介

  • 專利·核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國的Urokinase銷售情形

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的主要Urokinasemeka的市場佔有率

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Urokinase的劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為準
  • 各劑型的市場佔有率:以銷售量為準

第6章 中國的醫院的Urokinase的標準價格

  • Livzon Pharmaceutical Group Co., Ltd
  • NDPHARM
  • Tianjin Biochem Pharmaceutical Co., Ltd
  • PKU High-Tech Huatai Pharmaceutica
  • Liaoning Weixing Pharmaceutical Co., Ltd

第7章 中國市場中Urokinase的主要製藥公司

  • NDPHARM
  • Livzon Pharmaceutical Group Co., Ltd
  • Tianjin Biochem Pharmaceutical Co., Ltd
  • PKU High-Tech Huatai Pharmaceutica
  • Liaoning Weixing Pharmaceutical Co., Ltd

第8章 中國的Urokinase的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1508298

As a serine protease, urokinase is isolated from human urine or cultivated in kidneys. And it consists of LMW-tcu-PA and HMW-tcu-PA.

Activation of urokinase triggers a proteolysis cascade that participates in thrombolysis degradation. Urokinase not only immediately removes clot but also enhances the activity of ADP enzyme so as to inhibit the platelet aggregation and prevent thrombolysis. Activity of plasmin is improved when urokinase is given in the form of intravenous drip and falls back to normal level several hours later. As a traditional thrombolytic drug, urokinase is widely used in treating such thrombotic diseases as acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombus and deep vein thrombosis.

With aging population and unreasonable eating habit, the incidence of thrombotic disease has gone up, which promotes the demand for urokinase. According to CRI's market survey, the annual sales value of urokinase rose from CNY 18.20 million in 2010 to CNY 28.95 million in 2014 with CAGR during this period reaching 12.30%. NDPHARM had the largest market share of about 48.5% for sales value in 2014.

The market size of urokinase is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of urokinase in China
  • competitive landscape of urokinase market in China
  • price of urokinase made by different enterprises in China
  • market outlook of urokinase in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antithrombotic agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Urokinase

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Urokinase in China

  • 2.1. Patent and Approval Information of Urokinase in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Urokinase Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Urokinase Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Urokinase in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Urokinase in Chinese Hospitals in 2014

  • 6.1. Livzon Pharmaceutical Group Co., Ltd
  • 6.2. NDPHARM
  • 6.3. Tianjin Biochem Pharmaceutical Co., Ltd
  • 6.4. PKU High-Tech Huatai Pharmaceutica
  • 6.5. Liaoning Weixing Pharmaceutical Co., Ltd

7. Major Manufacturers of Urokinase in Chinese Market, 2010-2014

  • 7.1. NDPHARM
  • 7.2. Livzon Pharmaceutical Group Co., Ltd
  • 7.3. Tianjin Biochem Pharmaceutical Co., Ltd
  • 7.4. PKU High-Tech Huatai Pharmaceutica
  • 7.5. Liaoning Weixing Pharmaceutical Co., Ltd

8. Market Outlook of Urokinase in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Information of Urokinase in China
  • Chart Approval Information of Urokinase in China
  • Chart Sales Status of Urokinase in China
  • Chart Sales Value of Urokinase in China, 2010-2014
  • Chart Sales Value of Urokinase in Some Regions in China, 2010-2014
  • Chart Sales Volume of Urokinase in China, 2010-2014
  • Chart Sales Volume of Urokinase in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Urokinase Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by NDPHARM in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by Tianjin Biochem in China, 2010-2014
  • Chart Price of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by NDPHARM in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by Tianjin Biochem Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by PKU High-Tech Huatai in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by Liaoning Weixing in Some Chinese Cities in 2014
Back to Top